8SJ.F SHANGHAI JUNSHI BIO YC1

Healthcare Biotechnology Frankfurt Exchange
6.98 EUR
Close of Nov 11, 2026
1.69 3.04
Market cap
EUR 1.82B
P/E
-
P/B
2.31x
ROE
-13.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 8SJ.F undervalued?

Graham number

The Graham number of SHANGHAI JUNSHI BIO YC1 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

SHANGHAI JUNSHI BIO YC1 fundamental analysis

No fundamental analysis for SHANGHAI JUNSHI BIO YC1 yet.

SHANGHAI JUNSHI BIO YC1 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About SHANGHAI JUNSHI BIO YC1

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in phase III clinical trial to treat psoriatic and spondylitis; JS001sc, a subcutaneou…

Full company profile